SOURCE: The Bedford Report

The Bedford Report

July 27, 2011 08:16 ET

Advanced Cell Technology and Geron Aim to Shatter Stem Cell Myths

The Bedford Report Provides Equity Research on Advanced Cell Technology & Geron

NEW YORK, NY--(Marketwire - Jul 27, 2011) - With Americans spending in excess of $300 billion annually on drugs which typically only treat disease symptoms, regenerative therapies are garnering increased support. Scientists argue that stem cells are the future of healthcare, and that regenerative medicine is one of the most misunderstood fields in biotechnology. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on Advanced Cell Technology, Inc. (OTCBB: ACTC) and Geron Corporation (NASDAQ: GERN). Access to the full company reports can be found at:

www.bedfordreport.com/ACTC

www.bedfordreport.com/GERN

Headlines regarding the funding (or lack thereof) for embryonic stem cell research have a habit of moving all stem cell related stocks, even those not involved in the controversial sector. Very few publicly traded companies are actually engaged in embryonic stem cell research.

Geron Corporation is currently running clinical trials using embryonic stem cells. Geron is running Phase I trials to see if the cells can restore nerve function in patients who have suffered severe spinal-cord injuries.

The Bedford Report releases stock research on the Biotechnology Insurance Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Last month Advanced Cell Technology announced that it entered into a definitive collaborative agreement with Roslin Cells of Scotland. The two companies will work together to establish a bank of Good Manufacturing Practice-grade human embryonic stem cell (hESC) lines using ACT's "single-cell blastomere" technique for deriving hESC lines without destroying embryos.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information